Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in Apc Min /+ mice with natural ligands

Intestinal cancer is one of the most common human cancers. Aberrant activation of the canonical Wnt signaling cascade, for example, caused by adenomatous polyposis coli (APC) gene mutations, leads to increased stabilization and accumulation of β-catenin, resulting in initiation of intestinal carcino...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 106; no. 32; pp. 13481 - 13486
Main Authors Kawajiri, Kaname, Kobayashi, Yasuhito, Ohtake, Fumiaki, Ikuta, Togo, Matsushima, Yoshibumi, Mimura, Junsei, Pettersson, Sven, Pollenz, Richard S., Sakaki, Toshiyuki, Hirokawa, Takatsugu, Akiyama, Tetsu, Kurosumi, Masafumi, Poellinger, Lorenz, Kato, Shigeaki, Fujii-Kuriyama, Yoshiaki
Format Journal Article
LanguageEnglish
Published 11.08.2009
Online AccessGet full text

Cover

Loading…
More Information
Summary:Intestinal cancer is one of the most common human cancers. Aberrant activation of the canonical Wnt signaling cascade, for example, caused by adenomatous polyposis coli (APC) gene mutations, leads to increased stabilization and accumulation of β-catenin, resulting in initiation of intestinal carcinogenesis. The aryl hydrocarbon receptor (AhR) has dual roles in regulating intracellular protein levels both as a ligand-activated transcription factor and as a ligand-dependent E3 ubiquitin ligase. Here, we show that the AhR E3 ubiquitin ligase has a role in suppression of intestinal carcinogenesis by a previously undescribed ligand-dependent β-catenin degradation pathway that is independent of and parallel to the APC system. This function of AhR is activated by both xenobiotics and natural AhR ligands, such as indole derivatives that are converted from dietary tryptophan and glucosinolates by intestinal microbes, and suppresses intestinal tumor development in Apc Min /+ mice. These findings suggest that chemoprevention with naturally-occurring and chemically-designed AhR ligands can be used to successfully prevent intestinal cancers.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.0902132106